Politics, Policy & Law
Warp Speed reflections, master protocols & Biden’s COVID plan: a BioCentury podcast
On the latest edition of the BioCentury this Week podcast, BioCentury editors discuss the successes and limitations of Operation Warp Speed, proposals for streamlining master protocol trials and highlights for industry from the Biden administration’s COVID-19 plan.
Washington Editor Steve Usdin recaps his exit interview with Moncef Slaoui, who touted Warp Speed’s success in facilitating vaccine development, and acknowledged flaws in the initiative’s approach to vaccine administration and therapeutics development. Slaoui, who served as Warp Speed’s chief scientific adviser and co-leader, has stayed on as a consultant to the Biden administration.
Usdin also highlighted Slaoui’s comments on therapeutics development, namely, that the IV mAbs drug developers first products created too many logistical hurdles for widespread use, and that a mass of poorly designed trials diverted resources from more efficient master protocol studies, which were ultimately slow to implement.
“For future pandemics, and I would argue that this one isn’t over, it’s not too late for this one, a priority should be set for ensuring the monoclonal antibodies can be administered through sub-Q or IM injections,” says Usdin.